IL288266A - Gene therapy for Alzheimer's disease - Google Patents
Gene therapy for Alzheimer's diseaseInfo
- Publication number
- IL288266A IL288266A IL288266A IL28826621A IL288266A IL 288266 A IL288266 A IL 288266A IL 288266 A IL288266 A IL 288266A IL 28826621 A IL28826621 A IL 28826621A IL 288266 A IL288266 A IL 288266A
- Authority
- IL
- Israel
- Prior art keywords
- alzheimer
- disease
- gene therapy
- therapy
- gene
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852716P | 2019-05-24 | 2019-05-24 | |
| PCT/US2020/034040 WO2020242892A1 (en) | 2019-05-24 | 2020-05-21 | Gene therapy for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288266A true IL288266A (en) | 2022-01-01 |
Family
ID=73553511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288266A IL288266A (en) | 2019-05-24 | 2021-11-21 | Gene therapy for Alzheimer's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12540334B2 (https=) |
| EP (1) | EP3976637A4 (https=) |
| JP (1) | JP7686573B6 (https=) |
| CN (1) | CN114144425B (https=) |
| AU (1) | AU2020285638A1 (https=) |
| CA (1) | CA3141712A1 (https=) |
| IL (1) | IL288266A (https=) |
| WO (1) | WO2020242892A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3100946A1 (en) | 2018-05-22 | 2019-11-28 | The Brigham And Women's Hospital, Inc. | Gene therapy for alzheimer's disease |
| BR112022010373A2 (pt) | 2019-11-29 | 2022-08-16 | Paros Bio Inc | Terapia genética para doenças neurodegenerativas |
| CN118660970A (zh) * | 2022-01-29 | 2024-09-17 | 上海日馨医药科技股份有限公司 | 表达tpk的重组病毒及其治疗阿尔茨海默病的用途 |
| AU2023312939A1 (en) * | 2022-07-25 | 2025-03-06 | Katholieke Universiteit Leuven | Antisense oligonucleotides for treating a disease or condition associated with an abnormal processing of app |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
| JP2000506375A (ja) | 1996-01-26 | 2000-05-30 | エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 |
| AR020107A1 (es) | 1998-07-09 | 2002-04-10 | Boehringer Ingelheim Pharma | Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que |
| CA2333467A1 (en) | 1998-07-16 | 2000-01-27 | Incyte Pharmaceuticals, Inc. | Human presenilin-associated protein |
| US6979537B2 (en) | 2000-01-10 | 2005-12-27 | Scios, Inc. | Methods for identifying inhibitors of neuronal degeneration |
| US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| US7271313B2 (en) | 2003-04-09 | 2007-09-18 | The Brigham And Women's Hospital, Inc. | Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss |
| CA2528963A1 (en) | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| WO2005037226A2 (en) | 2003-10-17 | 2005-04-28 | Georgia Tech Research Corporation | Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders |
| PT1675956E (pt) | 2003-10-21 | 2010-11-04 | Merck Serono Sa | Sequência mínima de adn que actua como um isolador de cromatina e sua utilização na expressão de proteína |
| WO2005096781A2 (en) | 2004-04-06 | 2005-10-20 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using rna interference |
| JP5697297B2 (ja) | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| WO2005116250A2 (en) | 2004-05-26 | 2005-12-08 | Rosetta Genomics Ltd. | Viral and viral associated mirnas and uses thereof |
| US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| WO2009042727A1 (en) | 2007-09-24 | 2009-04-02 | The Johns Hopkins University | Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin |
| KR20120089743A (ko) | 2009-11-09 | 2012-08-13 | 제네포드 테라퓨틱스 에이비 | 생체 내에서 최적화된 뉴런 특이적 연속 도파 합성을 위한 신규한 바이러스 벡터 구성물 |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| CN103816540B (zh) | 2012-11-16 | 2018-01-02 | 中国科学院上海生命科学研究院 | 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用 |
| CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| HK1222673A1 (zh) | 2013-07-12 | 2017-07-07 | The Children's Hospital Of Philadelphia | Aav载体和用於抗aav(腺相关病毒)中和抗体的检测 |
| GB201404470D0 (en) * | 2014-03-13 | 2014-04-30 | Ucl Business Plc | Therapeutic methods and materials |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| WO2016118780A1 (en) * | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| WO2016154055A1 (en) | 2015-03-20 | 2016-09-29 | Bluebird Bio, Inc. | Vector formulations |
| WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| CN117018228A (zh) | 2016-05-27 | 2023-11-10 | 创思瑞普泰克斯公司 | 用合成信使rna治疗原发性纤毛运动障碍 |
| WO2018045022A1 (en) | 2016-08-30 | 2018-03-08 | University Of South Florida | Adipose derived stem cell exosomes and uses thereof |
| EP3573627A4 (en) * | 2017-01-24 | 2020-11-25 | Fred Hutchinson Cancer Research Center | SYSTEMS AND METHODS FOR EXPANSION OF HEMATOPOIETIC CELLS USING HYDROGELS |
| US11713470B2 (en) | 2017-03-20 | 2023-08-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeted gene therapies for pain and other neuro-related disorders |
| ES3039647T3 (en) | 2017-05-31 | 2025-10-23 | Arcturus Therapeutics Inc | Synthesis and structure of high potency rna therapeutics |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CA3100946A1 (en) | 2018-05-22 | 2019-11-28 | The Brigham And Women's Hospital, Inc. | Gene therapy for alzheimer's disease |
| BR112022010373A2 (pt) | 2019-11-29 | 2022-08-16 | Paros Bio Inc | Terapia genética para doenças neurodegenerativas |
| JP2023512079A (ja) | 2020-01-31 | 2023-03-23 | パロス バイオ インコーポレイテッド | ポリヌクレオチドサイレンシング及び置換を使用する神経変性障害のための遺伝子療法 |
-
2020
- 2020-05-21 JP JP2021569550A patent/JP7686573B6/ja active Active
- 2020-05-21 EP EP20813435.3A patent/EP3976637A4/en active Pending
- 2020-05-21 AU AU2020285638A patent/AU2020285638A1/en active Pending
- 2020-05-21 CA CA3141712A patent/CA3141712A1/en active Pending
- 2020-05-21 WO PCT/US2020/034040 patent/WO2020242892A1/en not_active Ceased
- 2020-05-21 US US17/613,612 patent/US12540334B2/en active Active
- 2020-05-21 CN CN202080052274.9A patent/CN114144425B/zh active Active
-
2021
- 2021-11-21 IL IL288266A patent/IL288266A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7686573B2 (ja) | 2025-06-02 |
| EP3976637A1 (en) | 2022-04-06 |
| WO2020242892A1 (en) | 2020-12-03 |
| CN114144425A (zh) | 2022-03-04 |
| JP7686573B6 (ja) | 2025-07-04 |
| AU2020285638A1 (en) | 2021-12-23 |
| US20220235374A1 (en) | 2022-07-28 |
| EP3976637A4 (en) | 2023-07-12 |
| CN114144425B (zh) | 2025-05-13 |
| JP2022533451A (ja) | 2022-07-22 |
| CA3141712A1 (en) | 2020-12-03 |
| US12540334B2 (en) | 2026-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278813A (en) | Gene therapy for Alzheimer's disease | |
| ZA202205344B (en) | Gene therapy for alzheimer's disease | |
| PT3873604T (pt) | Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina | |
| IL288266A (en) | Gene therapy for Alzheimer's disease | |
| IL285238A (en) | Gene therapy vectors for treatment of danon disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| IL280326A (en) | Small RNA contracts for Alzheimer's disease | |
| GB201522416D0 (en) | Wilson's disease gene therapy | |
| PL4284387T3 (pl) | Terapia podnosząca poziom NAD w chorobie Parkinsona | |
| GB201915753D0 (en) | Alzheimer's disease | |
| ZA202006126B (en) | Compounds for treating alzheimer's disease | |
| IL276701A (en) | Oligonucleotide therapy for Wilson's disease | |
| GB201817469D0 (en) | Gene therapy for retinal disease | |
| HK40070171A (en) | Gene therapy for alzheimer's disease | |
| HK40050811A (en) | Gene therapy for alzheimer's disease | |
| EP3244897A4 (en) | Methods for treating alzheimer's disease | |
| GB201911728D0 (en) | Bacterial composistions for the treatment of disease | |
| GB202200885D0 (en) | Nad-augmentation therapy for parkinson's disease | |
| AU2018903530A0 (en) | Treatment for Alzheimer's Disease | |
| GB201819758D0 (en) | Medicine for the treatment of Alzheimer's disease | |
| HK40082515A (en) | Compounds for treatment of alzheimer's disease | |
| HK40041162A (en) | Compounds for treating alzheimer's disease | |
| HK40079761A (en) | Anti-beta-amyloid antibody for treating alzheimer's disease | |
| HK40079762A (en) | Methods for treating parkinson's disease | |
| EP4072568A4 (en) | METHOD FOR TREATING PARKINSON'S DISEASE |